Abstract 1023MO
Background
Immune checkpoint blockade has emerged as a therapeutic strategy for cancers. The objective of this phase I study was to evaluate the safety/tolerability and describe immune-mediated effects of nivo in patients (pts) with HIV-associated ST.
Methods
Pts received nivo at 3 mg/kg q 2 wk, in two dose de-escalation cohorts stratified by CD4 count (Stratum 1: CD4 counts>200/uL and Stratum 2: CD4 count 100-200/uL) in pts with ST. An expansion cohort of 24 patients with CD4 count > 200 was then enrolled.
Results
A total of 37 pts were treated with nivo (n=4, 9, 24 for strata 1/2 and expansion cohorts). Histologies included Kaposi Sarcoma [KS](n=15), anal cancer [ca](n=5), lung ca (n=4) and other ST (n=13). No pts experienced dose-limiting toxicities (evaluable n=3 [stratum 1] and n=6 [stratum 2]). Treatment-related adverse events (AEs) were experienced by 14 (38%) pts. The most common treatment-related AEs were fatigue (n=5) and maculo-papular rash (n=4); of which, grade 3/4 severity was experienced by 2 pts each. Objective response rate (RR) by modified WHO criteria was 24% (9/37); with partial response (PR) in pts with KS (n=5), anal ca (n=1), colon ca (n=1), adenocarcinoma of the gall bladder (n=1), and squamous cell ca (n=1). There were no significant changes detected in HIV viral load (VL) during the study, which was undetectable for 97% of participants at baseline. Baseline median absolute CD4 was 315 (IQR, 225-434), and there was a trend for a reduction at 6-week (wk) post-treatment follow-up [f/u] (median difference: -35 (IQR, -83 to 37), p=0.072). Median CD4/CD8 ratio at baseline was 0.41 (IQR, 0.33-0.75) and increased by a median of 0.10 (IQR, -0.05 to 0.14, p=0.060) and 0.08 (IQR, 0 to 0.18, p=0.021) at 6- and 16 wk post-treatment f/u.
Conclusions
Nivo has acceptable safety in HIV patients with ST. Plasma viremia remained suppressed during the study suggesting no viral reactivation, and CD4/CD8 count ratio was increased at 16 wk post-treatment. A RR of 24% was observed in tumors known to be responsive to ICB. Thus, it is appropriate for HIV+ pts with ST treated with ART and a CD4+ T-cell count of greater than 100 cells/μL and undetectable VL to receive nivo in clinical trials and FDA-approved indications.
Clinical trial identification
NCT02408861.
Editorial acknowledgement
Legal entity responsible for the study
AMC (AIDS Malignancy Consortium).
Funding
NCI Grant #UM1CA121947.
Disclosure
L. Rajdev: Honoraria (self), Travel/Accommodation/Expenses: Bayer Pharmaceuticals. R. Baiocchi: Honoraria (self), Advisory/Consultancy, Leadership role, Research grant/Funding (self): Prelude Tx, Viracta. C-C.J. Wang, M.S. Lee: Research grant/Funding (institution): Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
1022MO - Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients
Presenter: Anders Kverneland
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1027MO - ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)
Presenter: Ulka Vaishampayan
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
LBA42 - POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy
Presenter: Sheela Rao
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1024MO - A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer
Presenter: Petri Bono
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1025MO - First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
Presenter: Ignacio Melero
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1026MO - Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours
Presenter: Daniel Karp
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Fiona Thistlethwaite
Session: Mini Oral - Investigational immunotherapy
Resources:
Slides
Webcast
Invited Discussant 1022MO and 1027MO
Presenter: Fiona Thistlethwaite
Session: Mini Oral - Investigational immunotherapy
Resources:
Slides
Webcast
Invited Discussant LBA42 and 1023MO
Presenter: Inge-Marie Svane
Session: Mini Oral - Investigational immunotherapy
Resources:
Slides
Webcast
Invited Discussant 1024MO, 1025MO and 1026MO
Presenter: Pedro Romero
Session: Mini Oral - Investigational immunotherapy
Resources:
Slides
Webcast